These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36586158)

  • 21. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
    Sugisawa N; Yamamoto J; Han Q; Tan Y; Tashiro Y; Nishino H; Inubushi S; Hamada K; Kawaguchi K; Unno M; Bouvet M; Hoffman RM
    Pancreas; 2021 Jan; 50(1):93-98. PubMed ID: 33370029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Installation of Recombinant Methioninase-producing
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
    Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease.
    Sato M; Han Q; Hozumi C; Kujiraoka H; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3885-3889. PubMed ID: 39197890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
    Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Jun; 44(6):2359-2367. PubMed ID: 38821601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
    Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
    Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Oshiro H; Tome Y; Kiyuna T; Yoon SN; Lwin TM; Han Q; Tan Y; Miyake K; Higuchi T; Sugisawa N; Katsuya Y; Park JH; Zang Z; Razmjooei S; Bouvet M; Clary B; Singh SR; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4667-4671. PubMed ID: 31519565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.
    Hu J; Cheung NK
    Int J Cancer; 2009 Apr; 124(7):1700-6. PubMed ID: 19089915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
    Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
    Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3777-3783. PubMed ID: 39197933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
    Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
    Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.
    Yano S; Takehara K; Zhao M; Tan Y; Han Q; Li S; Bouvet M; Fujiwara T; Hoffman RM
    Cell Cycle; 2016 Jul; 15(13):1715-23. PubMed ID: 27152859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
    Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
    Cells; 2019 May; 8(5):. PubMed ID: 31052611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
    Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
    Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant-methioninase-producing
    Kubota Y; Han Q; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(6):649-654. PubMed ID: 37927811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.
    Kubota Y; Han Q; Aoki Y; Masaki N; Obara K; Hamada K; Hozumi C; Wong ACW; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(3):272-281. PubMed ID: 37168964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.